Evidence map›Paper›PMID 42827227›Full record

ArticleCNS drugs2026

Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients.

Juri-Alexander Witt, Judit Catalán-Aguilar, Elisa Schütz, Randi von Wrede, Kevin G Hampel, Yulia Novitskaya, Rainer Surges, Mercedes Garcés, Birgitta Metternich, Kathrin Wagner and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Juri-Alexander WittDepartment of Epileptology, University Hospital Bonn (UKB), Venusberg-Campus 1, 53105, Bonn, Germany. juri-alexander.witt@ukbonn.de.ORCID http://orcid.org/0000-0001-5640-2592
Judit Catalán-AguilarInstitut d'Investigació en Psicologia dels Recursos Humans, del Desenvolupament Organitzacional i de la Qualitat de Vida Laboral (Idocal) / Department of Psychobiology, Psychology Center, Universitat de València, Valencia, Spain.
Elisa SchützEpilepsy Centre, Medical Centre-University of Freiburg, Freiburg, Germany.
Randi von WredeDepartment of Epileptology, University Hospital Bonn (UKB), Venusberg-Campus 1, 53105, Bonn, Germany.
Kevin G HampelRefractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Yulia NovitskayaEpilepsy Centre, Medical Centre-University of Freiburg, Freiburg, Germany.
Rainer SurgesDepartment of Epileptology, University Hospital Bonn (UKB), Venusberg-Campus 1, 53105, Bonn, Germany.
Mercedes GarcésRefractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Birgitta MetternichEpilepsy Centre, Medical Centre-University of Freiburg, Freiburg, Germany.
Kathrin WagnerEpilepsy Centre, Medical Centre-University of Freiburg, Freiburg, Germany.
Vicente VillanuevaRefractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Christoph HelmstaedterDepartment of Epileptology, University Hospital Bonn (UKB), Venusberg-Campus 1, 53105, Bonn, Germany.

Funding

Generalitat Valenciana CIBEFP/2023/164
6 · The paper itself

Abstract

backgroundTo date, no study has evaluated the objective cognitive effects of cenobamate (CNB) using an independent comparator group.

objectiveTo compare cognitive performance in individuals with epilepsy treated with CNB versus perampanel (PER), an antiseizure medication (ASM) without systematic negative effects on objective cognitive performance.

methodsThis retrospective cross-sectional multicentre study provides a comparative analysis of cognitive performance in patients with epilepsy treated with CNB versus PER. The cognitive assessment focused on executive functions (EpiTrack

resultsThe analysis included 600 individuals with epilepsy (mean age: 38.7 ± 12.9 years, 48.5% women), 200 of them with CNB (mean dose: 190.9 ± 94.1 mg/day; range 12.5-450.0) and a matched sample (sex, age, age at epilepsy onset, education) of 400 patients with PER (mean dose: 7.1 ± 3.0 mg/day; range 2.0-12.0). ANOVA indicated no difference in cognitive performance between patients treated with CNB versus PER (Bayes Factor [BF] = 0.207) but decisive evidence of a negative effect of more concomitant ASMs (BF = 9.5 × 10

conclusionThe study demonstrated comparable performance in executive functions in individuals treated with CNB or PER and confirmed the adverse effect of an increasing number of combined ASMs. This appears consistent with previous studies showing mostly stable performance after introduction of CNB. Our study was not suited to address previously claimed dose-dependent cognitive side effects and did not assess episodic memory.

Identifiers

PMID42827227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.